Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NOS3 | P29474 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | NOS2 | P35228 | 1/20 | 0.36 |
| ▸ | ACHE | P22303 | 10/20 | 0.35 |
| ▸ | GRIN1 | Q05586 | 9/20 | 0.35 |
| ▸ | GRIN2A | Q12879 | 9/20 | 0.35 |
| ▸ | BCHE | P06276 | 8/20 | 0.35 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GAA | P10253 | 1/20 | 0.34 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.33 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPC1 | O15118 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16872091 | 0.97 | NOS3 (0.39) | NOS3NOS1NOS2ACHEGRIN1 | |
| SCHEMBL16872034 | 0.81 | ACHE (0.35) | ACHEGRIN1GRIN2ABCHEPOLB | |
| SCHEMBL16872017 | 0.81 | MAPK1 (0.38) | GAATSHRCYP1A2CYP2C19ALDH1A1 | |
| SCHEMBL16872171 | 0.81 | ACHE (0.38) | NOS3NOS1NOS2ACHEGRIN1 | |
| SCHEMBL16872138 | 0.78 | ACHE (0.36) | NOS3NOS1NOS2ACHEGRIN1 | |
| SCHEMBL16872294 | 0.75 | KDM4E (0.39) | POLBGAATSHRCYP1A2CYP2C19 | |
| SCHEMBL4928360 | 0.75 | NOS3 (0.55) | NOS3NOS1NOS2ACHEGRIN1 | |
| SCHEMBL29770726 | 0.75 | NOS3 (0.55) | NOS3NOS1NOS2ACHEGRIN1 | |
| SCHEMBL7327037 | 0.73 | BCHE (0.46) | ACHEGRIN1GRIN2ABCHETSHR | |
| SCHEMBL16872037 | 0.72 | MAPK1 (0.38) | POLBGAATSHRCYP1A2CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150225404-A1 | PYRIDINE DERIVATIVE AND MEDICINE | NIPPON SHINYAKU CO., LTD. (JP) | 2015-08-13 | — | — | US | disclosed |
| EP-2891656-A1 | PYRIDINE DERIVATIVE AND MEDICINE | Nippon Shinyaku Co., Ltd. (JP) | 2015-07-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150225404-A1 | PYRIDINE DERIVATIVE AND MEDICINE | TRPV1, TRPV5, TRPM5 | NOS3 2257/4885NOS1 2519/4885NOS2 2472/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.